AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 4 out of 5

ABBV News and Commentary

Caps

How do you think ABBV will perform against the market?

Add Stock to CAPS Watchlist

All Players

461 Outperform
11 Underperform
 

All-Star Players

104 Outperform
2 Underperform
 

Wall Street

8 Outperform
0 Underperform
 

Top ABBV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bdbcalm (< 20)
Submitted February 15, 2015

Sold off due to patent cliff concerns and Hep C drug discounts. I believe this is an overreaction and the stock will recover. There is more in the pipeline than the P/E - 13 - would imply.

TMFSpiffyPop (99.85)
Submitted January 09, 2015

This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More

ABBV VS S&P 500 (SPY)

Fools bullish on ABBV are also bullish on:

Fools bearish on ABBV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ABBV.

Recs

0
Member Avatar redrover1001 (39.00) Submitted: 7/13/2018 1:44:36 PM : Outperform Start Price: $91.14 ABBV Score: -0.71

Pipeline, Partnerships and Profit

https://www.fool.com/investing/2018/07/13/x-overlooked-biotech-stocks-to-buy-now.aspx
AbbVie Inc.: Partnerships big and small

The world's top-selling drug, Humira, generates some tremendous cash flows for AbbVie, which it has deftly invested into new drug candidates at various stages of development. For example, the company shelled out a whopping $21 billion for rights to a blood cancer drug called Imbruvica in 2015. Since becoming the first chemo-free treatment option for the most commonly diagnosed form of leukemia, Imbruvica sales shot up, and it finished the first quarter on pace to contribute more than $3 billion to the company's top line this year.

https://www.fool.com/investing/2018/07/06/3-top-biotech-stocks-to-buy-in-july.aspx
What about value investors? AbbVie stock trades at only 10.4 times expected earnings. That's dirt-cheap for a company with the world's best-selling drug and a stable of other strong performers.

Recs

0
Member Avatar mingdom (90.87) Submitted: 6/17/2018 3:09:49 PM : Outperform Start Price: $98.16 ABBV Score: -5.85

Looks cheap to me

Recs

0
Member Avatar TCuell (55.95) Submitted: 6/3/2018 12:04:06 PM : Outperform Start Price: $97.49 ABBV Score: -5.55

Possible breakout w new drug therapies

Leaderboard

Find the members with the highest scoring picks in ABBV.

Score Leader

armydave

armydave (68.07) Score: +152.33

The Score Leader is the player with the highest score across all their picks in ABBV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. valari25 99.34 1/10/2013 10/26/2015 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
cooleyly 50.64 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
GW1000 91.67 1/10/2013 7/6/2018 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
drjohn432 < 20 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. mattmmurphy 66.15 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
concealedweaponR 29.41 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
deliman723 64.02 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
pirotta < 20 1/10/2013 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
armydave 68.07 1/10/2013 12/6/2017 Outperform 5Y $27.45 +243.88% +91.55% +152.33 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. kinosternon 98.98 1/9/2013 Outperform 5Y $27.58 +242.32% +92.43% +149.88 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCitigroup 92.53 2/23/2016 Outperform NS $50.88 +85.54% +44.88% +40.67 0 Comment
TrackDeutscheSec 87.22 10/21/2014 Outperform NS $48.41 +95.01% +46.63% +48.38 0 Comment
trackguggenheim 20.68 10/2/2014 Outperform NS $50.02 +88.73% +44.74% +43.98 0 Comment
TrackBarclaysCap 91.09 7/2/2014 Outperform NS $49.39 +91.12% +42.63% +48.49 0 Comment
TrackGoldmanSach 78.83 12/3/2013 Outperform NS $41.66 +126.61% +56.20% +70.41 0 Comment
TrackBMOCapital < 20 10/28/2013 Outperform NS $41.66 +126.61% +59.79% +66.82 0 Comment
TrackArgus 85.51 8/12/2013 Outperform NS $37.58 +151.22% +66.84% +84.38 0 Comment
TrackJimCramer 85.65 6/10/2013 Outperform 3W $36.58 +158.07% +70.55% +87.52 0 Comment
TrackCreditSuiss 89.05 2/7/2013 Underperform NS $34.70 +100.33% +37.54% -62.79 12/5/2014 @ $69.52 0 Comment
TrackJimCramer 85.65 1/15/2013 Underperform 3W $34.28 +28.11% +12.06% -16.05 6/10/2013 @ $43.92 0 Comment

Featured Broker Partners


Advertisement